Program
Z 338
Also written as “Z-338”, “YM443” and “Acotiamide hydrochloride hydrate”.
Its studies are mostly in Dyspepsia, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Zeria Pharmaceutical | 70 open or running | phase 3since Sep 25, 2008 | Feb 28, 2006 | none ahead |
| Astellas Pharma | 40 open or running | phase 3since Sep 30, 2008 | Jan 26, 2005 | none ahead |
| Getz Pharma | 11 open or running | phase 3since Sep 12, 2025 | Sep 12, 2025 | Dec 30, 2026phase 3 · NCT07174297 |
Also a collaborator on its studies: astellas-pharma-us-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 26, 2005First study: phase 2 study in DyspepsiaNew to Astellas PharmaAstellas Pharma · NCT00102310 · 416 enrolled · United States
- Feb 28, 2006Zeria Pharmaceutical's first study: phase 2 study in DyspepsiaNew to Zeria PharmaceuticalZeria Pharmaceutical · NCT00298194 · 52 enrolled · Australia
- May 8, 2006Phase 2 study in Functional DyspepsiaZeria Pharmaceutical · NCT00323817 · 282 enrolled · Belgium
- Jun 2, 2006Phase 2 study in Functional DyspepsiaZeria Pharmaceutical · NCT00333372 · 440 enrolled · Japan
- Apr 9, 2007Phase 2 study in Functioanl DyspepsiaZeria Pharmaceutical · NCT00458328 · 40 enrolled · Japan
- Sep 25, 2008Phase 3 study in Functional DyspepsiaZeria Pharmaceutical · NCT00761358 · 820 enrolled · Japan
- Sep 30, 2008Phase 3 study in DyspepsiaAstellas Pharma · NCT00764374 · 412 enrolled · Japan
- Feb 23, 2009Phase 1 study in Functional DyspepsiaAstellas Pharma · NCT00850746 · 80 enrolled · United States
- Jun 15, 2009Phase 1 study in HealthyAstellas Pharma · NCT00920998 · 30 enrolled · Japan
- Oct 26, 2013Phase 3 study in DyspepsiaZeria Pharmaceutical · NCT01973790 · 207 enrolled · Belgium, Bulgaria, Latvia and more
- Aug 19, 2020Phase 3 study in Functional DyspepsiaZeria Pharmaceutical · NCT04526119 · 55 enrolled · Japan
- Sep 12, 2025Getz Pharma's first study: phase 3 study in Postprandial Distress SyndromeNew to Getz PharmaGetz Pharma · NCT07174297 · 152 planned
Ahead
- Dec 30, 2026Primary completion: phase 3 study in Postprandial Distress SyndromeGetz Pharma · NCT07174297
TargetBeta
“Acetylcholinesterase inhibitor”ChEMBL 37, by rule
Other programs on ACHE
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Donepezilrule | Eisai | phase 4 | 83 |
| huperzine Arule | wanbangde-pharmaceutical-group-co-ltd | phase 4 | 7 |
| benzgalantamine gluconaterule | alpha-cognition-inc | phase 4 | 1 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07174297Postprandial Distress Syndrome | 3 | Not yet recruiting | Getz Pharma | Dec 30, 2026 | 152 |
| NCT04526119Functional Dyspepsia · Japan | 3 | Completed | Zeria Pharmaceutical | Mar 2, 2026 | 55 |
| NCT01973790Dyspepsia · Belgium, Bulgaria, Latvia and more | 3 | Completed | Zeria Pharmaceutical | Nov 2016 | 207 |
| NCT00920998Healthy · Japan | 1 | Completed | Astellas Pharma | Jun 2009 | 30 |
| NCT00850746Functional Dyspepsia · United States | 1 | Completed | Astellas Pharma | Apr 2009 | 80 |
| NCT00764374Dyspepsia · Japan | 3 | Completed | Astellas Pharma | Dec 2009 | 412 |
| NCT00761358Functional Dyspepsia · Japan | 3 | Completed | Zeria Pharmaceutical | Jun 2010 | 820 |
| NCT00458328Functioanl Dyspepsia · Japan | 2 | Completed | Zeria Pharmaceutical | Sep 2009 | 40 |
| NCT00333372Functional Dyspepsia · Japan | 2 | Completed | Zeria Pharmaceutical | 440 | |
| NCT00323817Functional Dyspepsia · Belgium | 2 | Completed | Zeria Pharmaceutical | Apr 2009 | 282 |
| NCT00298194Dyspepsia · Australia | 2 | Completed | Zeria Pharmaceutical | Jul 2008 | 52 |
| NCT00102310Dyspepsia · United States | 2 | Completed | Astellas Pharma | Mar 11, 2006 | 416 |
How it is read
Names in the registry
- “Z-338”, 7 entries
- “YM443”, 3 entries
- “Acotiamide hydrochloride hydrate”, 1 entry
- “Acotiamide”, 1 entry
Conditions, from the studies’ own filings
- Dyspepsia, 10 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.